Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alterity Therapeutics (ATHE) Cash & Equivalents (2016 - 2025)

Alterity Therapeutics has reported Cash & Equivalents over the past 5 years, most recently at $10.1 million for Q2 2019.

  • For Q2 2019, Cash & Equivalents fell 12.55% year-over-year to $10.1 million; the TTM value through Jun 2019 reached $10.1 million, down 12.55%, while the annual FY2019 figure was $10.1 million, 12.55% down from the prior year.
  • Cash & Equivalents for Q2 2019 was $10.1 million at Alterity Therapeutics, up from $6.0 million in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $27.1 million in Q2 2015 and troughed at $6.0 million in Q4 2018.
  • A 5-year average of $16.7 million and a median of $16.4 million in 2017 define the central range for Cash & Equivalents.
  • Biggest five-year swings in Cash & Equivalents: rose 1.66% in 2016 and later crashed 60.72% in 2018.
  • Year by year, Cash & Equivalents stood at $20.9 million in 2015, then grew by 1.66% to $21.3 million in 2016, then dropped by 27.98% to $15.3 million in 2017, then crashed by 60.72% to $6.0 million in 2018, then soared by 67.72% to $10.1 million in 2019.
  • Business Quant data shows Cash & Equivalents for ATHE at $10.1 million in Q2 2019, $6.0 million in Q4 2018, and $11.5 million in Q2 2018.